361 related articles for article (PubMed ID: 8607111)
21. Antithrombotic activity in vivo of SDZ 217-766, a low-molecular weight thrombin inhibitor in comparison to heparin.
Tapparelli C; Metternich R; Gfeller P; Gafner B; Powling M
Thromb Haemost; 1995 Apr; 73(4):641-7. PubMed ID: 7495072
[TBL] [Abstract][Full Text] [Related]
22. Experimental studies on the relative efficacy of dermatan sulphate and heparin as antithrombotic agents.
Merton RE; Thomas DP
Thromb Haemost; 1987 Oct; 58(3):839-42. PubMed ID: 3433248
[TBL] [Abstract][Full Text] [Related]
23. SR123781A, a synthetic heparin mimetic.
Herbert JM; Hérault JP; Bernat A; Savi P; Schaeffer P; Driguez PA; Duchaussoy P; Petitou M
Thromb Haemost; 2001 May; 85(5):852-60. PubMed ID: 11372679
[TBL] [Abstract][Full Text] [Related]
24. [Evaluation of hospital cost of six days of treatment of deep venous thrombosis. Comparison of subcutaneous nadroparin and intravenous heparin in 40 patients].
Lévesque H; Cailleux N; Vasse D; Legallicier B; Moore N; Borg JY; Hantute N; Thuillez C; Courtois H
Therapie; 1994; 49(2):101-5. PubMed ID: 7817331
[TBL] [Abstract][Full Text] [Related]
25. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
[TBL] [Abstract][Full Text] [Related]
26. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
[TBL] [Abstract][Full Text] [Related]
27. Pharmacological actions of sulodexide.
Ofosu FA
Semin Thromb Hemost; 1998; 24(2):127-38. PubMed ID: 9579633
[TBL] [Abstract][Full Text] [Related]
28. Modulation of procoagulant activity of extracellular endothelial matrix by anti-tissue factor antibody and the synthetic peptide Arg-Gly-Asp-Val. Experiments with flowing non-anticoagulated human blood.
Salatti JA; Anton P; Nemerson Y; Sakariassen KS
Blood Coagul Fibrinolysis; 1993 Dec; 4(6):881-90. PubMed ID: 8148480
[TBL] [Abstract][Full Text] [Related]
29. [Use of the low-molecular heparin, Fraxiparine, during hemodialysis].
Monhart V; Petrů K
Cas Lek Cesk; 1998 Jan; 137(1):18-21. PubMed ID: 9511272
[TBL] [Abstract][Full Text] [Related]
30. Antithrombotic and anticoagulant activities of a low molecular weight fucoidan by the subcutaneous route.
Millet J; Jouault SC; Mauray S; Theveniaux J; Sternberg C; Boisson Vidal C; Fischer AM
Thromb Haemost; 1999 Mar; 81(3):391-5. PubMed ID: 10102467
[TBL] [Abstract][Full Text] [Related]
31. Pharmacological properties of CY 216 and of its ACLM and BCLM components in the rabbit.
Peyrou V; Lormeau JC; Caranobe C; Gabaig AM; Crepon B; Saivin S; Houin G; Sié P; Boneu B
Thromb Haemost; 1994 Aug; 72(2):268-74. PubMed ID: 7831664
[TBL] [Abstract][Full Text] [Related]
32. Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.
Biemond BJ; Perzborn E; Friederich PW; Levi M; Buetehorn U; Büller HR
Thromb Haemost; 2007 Mar; 97(3):471-7. PubMed ID: 17334516
[TBL] [Abstract][Full Text] [Related]
33. Dose response relationships of anticoagulant activities after subcutaneous administration of two low molecular weight heparins in healthy individuals.
Hellstern P; Kiehl R; von Blohn G; Köhler M; Meierhenrich U; Wenzel E
Thromb Haemost; 1986 Oct; 56(2):225-8. PubMed ID: 3810557
[TBL] [Abstract][Full Text] [Related]
34. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
Kakkar VV; Howes J; Sharma V; Kadziola Z
Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
[TBL] [Abstract][Full Text] [Related]
35. Effects of heparin oligosaccharides with high affinity for antithrombin III in experimental venous thrombosis.
Thomas DP; Merton RE; Barrowcliffe TW; Thunberg L; Lindahl U
Thromb Haemost; 1982 Jun; 47(3):244-8. PubMed ID: 7112499
[TBL] [Abstract][Full Text] [Related]
36. Haemodialysis with low MW heparin: dosage requirements for the elimination of extracorporeal fibrin formation.
Lane DA; Ireland H; Flynn A; Anastassiades E; Curtis JR
Nephrol Dial Transplant; 1986; 1(3):179-87. PubMed ID: 2955253
[TBL] [Abstract][Full Text] [Related]
37. Effects of napsagatran (Ro 46-6240), a new synthetic thrombin inhibitor and of heparin in a canine model of coronary artery thrombosis: comparison with an ex vivo annular perfusion chamber model.
Roux S; Tschopp T; Baumgartner HR
J Pharmacol Exp Ther; 1996 Apr; 277(1):71-8. PubMed ID: 8613969
[TBL] [Abstract][Full Text] [Related]
38. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis.
Lopaciuk S; Bielska-Falda H; Noszczyk W; Bielawiec M; Witkiewicz W; Filipecki S; Michalak J; Ciesielski L; Mackiewicz Z; Czestochowska E; Zawilska K; Cencora A
Thromb Haemost; 1999 Jan; 81(1):26-31. PubMed ID: 9974369
[TBL] [Abstract][Full Text] [Related]
39. Different effects of enoxaparin and unfractionated heparin on some thrombogenesis markers during hemodialysis: a cross-over study.
Naumnik B; Pawlak K; Myśliwiec M
Thromb Res; 2009 Feb; 123(4):631-6. PubMed ID: 18234290
[TBL] [Abstract][Full Text] [Related]
40. Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.
Salvioni A; Casilli F; Assanelli E; Grazi M; Marenzi G; Guazzi MD
Thromb Haemost; 2001 Oct; 86(4):991-4. PubMed ID: 11686357
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
